Properties (58)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
chemotherapy drug
|
| gptkbp:activeDuring |
doxorubicin
|
| gptkbp:administrativeDivision |
every 4 weeks
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:brand |
Doxorubicin liposome
|
| gptkbp:chemicalFormula |
gptkb:doxorubicin_hydrochloride
anthracycline |
| gptkbp:clinicalTrials |
Phase II
combination therapy Phase III Phase I monotherapy |
| gptkbp:contraindication |
allergic reactions
pregnancy heart disease infusion reactions cardiotoxicity lactation secondary malignancies |
| gptkbp:dosageForm |
injection
2 mg/mL |
| gptkbp:drugInterdiction |
CYP3A4 inhibitors
CYP3A4 inducers |
| gptkbp:formulation |
liposomal
|
| gptkbp:hasPopulation |
children
adults |
| https://www.w3.org/2000/01/rdf-schema#label |
Doxil
|
| gptkbp:is_monitored_by |
gptkb:electrocardiogram_(ECG)
liver function tests kidney function tests |
| gptkbp:mandates |
ovarian cancer
breast cancer multiple myeloma |
| gptkbp:manufacturer |
gptkb:Johnson_&_Johnson
|
| gptkbp:marketedAs |
gptkb:Doxil
|
| gptkbp:offers |
varies by location
expensive |
| gptkbp:packaging |
vial
|
| gptkbp:patentStatus |
patented
generic available |
| gptkbp:providesGuidelinesFor |
trained personnel
aseptic_technique |
| gptkbp:researchAreas |
clinical trials
oncology pharmacology |
| gptkbp:route |
intravenous
|
| gptkbp:safetyFeatures |
monitor blood counts
avoid live vaccines monitor heart function |
| gptkbp:sideEffect |
fatigue
nausea mouth sores low blood cell counts |
| gptkbp:storage |
room temperature
protected from light |
| gptkbp:triggerType |
inhibits DNA synthesis
intercalates DNA |
| gptkbp:usedFor |
treating cancer
|